91ÌÒÉ«

ISSN: 2167-065X

Clinical Pharmacology & Biopharmaceutics
Open 91ÌÒÉ«

Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open 91ÌÒÉ« Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open 91ÌÒÉ« Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Citations : 1089

Indexed In
  • CAS Source Index (CASSI)
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Genamics JournalSeek
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • Publons
  • Euro Pub
  • ICMJE
Share This Page

Renal transplantation in HIV-infected patients: The first Portuguese review

International Conference and Expo on Biopharmaceutics

Sara Querido

Centro Hospitalar de Lisboa Ocidental, Portugal

Posters-Accepted Abstracts: Clin Pharmacol Biopharm

DOI:

Abstract
With the introduction of Combination Antiretroviral Therapy (cART), prognosis of HIV infection has been improved and Kidney Transplantation (KT) in HIV positive patients became possible. We reviewed the demographic, clinical, laboratorial and therapeutic data of all the HIV-infected patients who underwent KT prior between 2009 (first KT in Portugal in a HIV-infected patient) and May 2014. Case accrual was through all Portuguese KT centers where a KT in a HIV-infected patient was performed. Patients were transplanted following the American and Spanish guideline recommendations that included maintenance on cART, undetectable plasma HIV RNA copies and absolute CD4 counts of at least 200 cells/�¼l in the last 6 months. Fourteen KT were performed on men, 3 KT on women. The mean age of patients at the time of transplantation was 49.9�±11.7 years. HIV status was known for 12�±5 years. Eight patients had AIDS in the past and all patients received grafts from deceased donors. Twelve patients (64.7%) received induction therapy with basiliximab and two patients had early graft loss. In 2 patients humoral rejection was diagnosed and in 3 patients, cellular rejection. Two patients died and one additional patient had early graft loss. KT is a possible, but challenging, renal replacement therapy in selected HIV patients. Even in those with AIDS criteria in the past, when the disease is controlled, and after the reconstitution of the immune system with cART, KT can be performed. Nevertheless, the risk-benefit ratio for each patient needs to be taken in consideration.
Biography

Email: saraqueridoconde@gmail.com

International Conferences 2025-26
 
Meet Inspiring Speakers and Experts at our 3000+ Global

Conferences by Country

Medical & Clinical Conferences

Conferences By Subject

Top